Eradivir Secures $10.25M for Influenza Study
Biotech firm Eradivir raises $10.25M for Phase 2a EV25 study, aiming to revolutionize influenza treatment.
- Latest
- Trending
Biotech firm Eradivir raises $10.25M for Phase 2a EV25 study, aiming to revolutionize influenza treatment.
UCF scientist's device captures and converts CO2 into valuable chemicals, promising a faster, cheaper carbon pollution solution.
AI in drug discovery market to skyrocket, reaching USD 11,874.24 million by 2032, with a CAGR of 37.5%.
Explainable AI offers transparency in AI-driven drug discovery, providing insights into antibiotic development.
Battelle has advanced a new technology to effectively eliminate PFAS, addressing the persistent 'forever chemicals' issue.
AI-designed proteins transform with molecular switches, paving new paths in biotechnology innovation and drug delivery.
Recursion Pharmaceuticals merges with Exscientia to revolutionize drug discovery, bringing new treatments to market more quickly.
Discover Piper Sandler's eight high-quality defensive biotech stocks poised to thrive in volatile markets.
AbCellera Biologics Inc. progresses with their TCE platform and strategic partnerships, aiming for CTA submissions in Q2 2025.
America's crackdown on Chinese biotech could lead to drug shortages and higher costs, impacting patients without delivering promised security benefits.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.